CoChat
Sign Up
Cited by 615Diabetes and associated disordersT-cell and B-cell ImmunologyDiabetes Management and Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

Open access
Orban, Tihamer, Bundy, Brian, Becker, Dorothy J, DiMeglio, Linda A, Gitelman, Stephen E, Goland, Robin, Gottlieb, Peter A, Greenbaum, Carla J, Marks, Jennifer B, Monzavi, Roshanak, Moran, Antoinette, Raskin, Philip, Rodriguez, Henry, Russell, William E, Schatz, Desmond, Wherrett, Diane, Wilson, Darrell M, Krischer, Jeffrey P, Skyler, Jay S·2011·The Lancet
DOI 10.1016/s0140-6736(11)60886-6PMC PMC3462593
Open this paper in CoChat — free account

Abstract

Background The immunopathogenesis of type 1 diabetes mellitus is associated with T-cell autoimmunity. To be fully active, immune T cells need a co-stimulatory signal in addition to the main antigen-driven signal. Abatacept modulates co-stimulation and prevents full T-cell activation. We evaluated the effect of abatacept in recent-onset type 1 diabetes. Methods In this multicentre, double-blind, randomised controlled trial, patients aged 6-45 years recently diagnosed with type 1 diabetes were randomly assigned (2:1) to receive abatacept (10 mg/kg, maximum 1000 mg per dose) or placebo infusions intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years. Computer-generated permuted block randomisation was used, with a block size of 3 and stratified by participating site. Neither patients nor research personnel were aware of treatment assignments. The primary outcome was baseline-adjusted geometric mean 2-h area-under-the-curve (AUC) serum C-peptide concentration after a mixed-meal tolerance test at 2 years' follow-up. Analysis was by intention to treat for all patients for whom data were available. This trial is registered at ClinicalTrials.gov, NCT00505375. Findings 112 patients were assigned to treatment groups (77 abatacept, 35 placebo). Adjusted C-peptide AUC was 59% (95% CI 6·1-112) higher at 2 years with abatacept (n=73, 0·378 nmol/L) than with placebo (n=30, 0·238 nmol/L; p=0·0029). The difference between groups was present throughout the trial, with an estimated 9·6 months' delay (95% CI 3·47-15·6) in C-peptide reduction with abatacept. There were few infusion-related adverse events (36 reactions occurred in 17 [22%] patients on abatacept and 11 reactions in six [17%] on placebo). There was no increase in infections (32 [42%] patients on abatacept vs 15 [43%] on placebo) or neutropenia (seven [9%] vs five [14%]). Interpretation Co-stimulation modulation with abatacept slowed reduction in β-cell function over 2 years. The beneficial effect suggests that T-cell activation still occurs around the time of clinical diagnosis of type 1 diabetes. Yet, despite continued administration of abatacept over 24 months, the decrease in β-cell function with abatacept was parallel to that with placebo after 6 months of treatment, causing us to speculate that T-cell activation lessens with time. Further observation will establish whether the beneficial effect continues after cessation of abatacept infusions. Funding US National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)60886-6

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

Sorted by citations

Items 301–400 of 615

Related

See all

Metadata

Authors
Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Marks, J. B., Monzavi, R., Moran, A., Raskin, P., Rodriguez, H., Russell, W. E., Schatz, D., Wherrett, D., Wilson, D. M., Krischer, J. P., & Skyler, J. S.
Affiliations
  • Joslin Diabetes Center (US)
  • University of South Florida (US)
  • University of Pittsburgh (US)
  • Indiana University School of Medicine (US)
  • University of California, San Francisco (US)
  • Columbia University (US)
  • Benaroya Research Institute (US)
  • University of Miami (US)
  • Children's Hospital Los Angeles (US)
  • University of Minnesota (US)
  • The University of Texas Southwestern Medical Center (US)
  • Vanderbilt University (US)
  • University of Florida (US)
  • University of Toronto (CA)
  • Stanford University (US)
Corresponding author
Skyler, Jay S
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2011-07
Volume
378
Issue
9789
Pages
412-419
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(11)60886-6
PMC
PMC3462593
OpenAlex
W2154694193
Cited by
612
References
31
Citations by year
2026: 26 · 2025: 40 · 2024: 52 · 2023: 30 · 2022: 33 · 2021: 34 · 2020: 43 · 2019: 32 · 2018: 41 · 2017: 31 · 2016: 43 · 2015: 45 · 2014: 46 · 2013: 57 · 2012: 45
FWCI
31.92
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
Funders
  • Sanofi
  • University of Florida
  • University of Washington
  • MacroGenics
  • Novo Nordisk
  • National Institutes of Health (5ul1rr031986-02)
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-084565, U01DK061040, U01DK085461, U01DK085505, U01DK085499, U01DK061055, U01DK061036, U01DK061010, U01DK061058, U01DK061034, U01DK085504, U01DK061042, U01DK085463, U01DK085453, UC4DK117009, U01DK061041, U01DK085466, U01DK085509, U01 DK-061016)
  • U.S. National Library of Medicine (HHSN267200800019C)
  • National Center for Research Resources (UL1RR029890, UL1RR024131, M01RR000400, UL1-RR031986, UL1RR025744, UL1RR024153, UL1RR024982, UL1RR025761, M01-RR00400, UL1RR024975, UL1RR024139, UL1RR025780)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
abatacept, type 1 diabetes, recent-onset type 1 diabetes, T cell costimulation, T cell-mediated autoimmunity, C-peptide, beta-cell function, immunomodulation, mixed meal tolerance test, infusion-related adverse events, infection, neutropenia, children and adolescents, disease progression, HLA-DR
MeSH terms
Abatacept, Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, T-Lymphocytes, Autoimmunity, Randomized Controlled Trials as Topic, Immunoconjugates, Insulin-Secreting Cells, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review